NO20074258L - Pyridin-2-karboksamidderivater som MGLUR5 antagonister - Google Patents
Pyridin-2-karboksamidderivater som MGLUR5 antagonisterInfo
- Publication number
- NO20074258L NO20074258L NO20074258A NO20074258A NO20074258L NO 20074258 L NO20074258 L NO 20074258L NO 20074258 A NO20074258 A NO 20074258A NO 20074258 A NO20074258 A NO 20074258A NO 20074258 L NO20074258 L NO 20074258L
- Authority
- NO
- Norway
- Prior art keywords
- pyridine
- carboxamide derivatives
- mglur5 antagonists
- preparation
- mglur5
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05101701 | 2005-03-04 | ||
| PCT/EP2006/001638 WO2006094639A1 (en) | 2005-03-04 | 2006-02-23 | Pyridine-2-carboxamide derivatives as mglur5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074258L true NO20074258L (no) | 2007-11-27 |
Family
ID=36524927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074258A NO20074258L (no) | 2005-03-04 | 2007-08-21 | Pyridin-2-karboksamidderivater som MGLUR5 antagonister |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7414060B2 (es) |
| EP (1) | EP1858854B1 (es) |
| JP (1) | JP4767975B2 (es) |
| KR (1) | KR100929942B1 (es) |
| CN (1) | CN101133027B (es) |
| AR (1) | AR054232A1 (es) |
| AU (1) | AU2006222289A1 (es) |
| BR (1) | BRPI0607583A2 (es) |
| CA (1) | CA2599974C (es) |
| ES (1) | ES2476840T3 (es) |
| IL (1) | IL185326A0 (es) |
| MX (1) | MX2007010414A (es) |
| NO (1) | NO20074258L (es) |
| RU (1) | RU2411237C2 (es) |
| TW (1) | TW200700391A (es) |
| WO (1) | WO2006094639A1 (es) |
| ZA (1) | ZA200707141B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| US7414060B2 (en) * | 2005-03-04 | 2008-08-19 | Hoffmann-La Roche Inc. | Pyridine-2-carboxyamide derivatives |
| AR058554A1 (es) * | 2005-12-20 | 2008-02-13 | Novartis Ag | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| US20100249136A1 (en) * | 2007-10-12 | 2010-09-30 | Daniel Umbricht | Organic compounds |
| WO2009047303A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder |
| WO2009078432A1 (ja) * | 2007-12-18 | 2009-06-25 | Taisho Pharmaceutical Co., Ltd. | 1-アルキル-4-アミノ-1h-ピラゾール-3-カルボキサミド化合物 |
| WO2010100050A1 (en) * | 2009-03-05 | 2010-09-10 | F. Hoffmann-La Roche Ag | Pyridine-2-yl-carboxylic acid amides |
| CA2774373A1 (en) * | 2009-09-17 | 2011-03-24 | Vanderbilt University | Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| JP2013508413A (ja) * | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | mGluR4アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| WO2011125568A1 (ja) * | 2010-04-06 | 2011-10-13 | 日本曹達株式会社 | 含窒素複素環化合物及びその製造方法 |
| AU2014201037B9 (en) * | 2010-04-06 | 2015-11-19 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and method for producing same |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| EP3071568A1 (en) | 2013-11-19 | 2016-09-28 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5 |
| US9533982B2 (en) | 2014-03-20 | 2017-01-03 | Vanderbilt University | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| CA3090545A1 (en) | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
| CN112624968B (zh) * | 2021-01-18 | 2022-03-08 | 阿里生物新材料(常州)有限公司 | 一种5-氨基-3-氰基吡啶甲酸甲酯盐酸盐的合成方法 |
| WO2025093610A1 (en) | 2023-10-31 | 2025-05-08 | Intervet International B.V. | A process for preparing 2-amino-3,5-difluoropyridine or a salt thereof |
| WO2025093624A1 (en) | 2023-10-31 | 2025-05-08 | Intervet International B.V. | A process for preparing 3,5-difluoro-2-pyridinecarboxamide |
| WO2025093631A1 (en) | 2023-10-31 | 2025-05-08 | Intervet International B.V. | A process for preparing 2-amino-3,5-difluoropyridine or a salt thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| WO2000050398A2 (en) * | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| CN1361768A (zh) * | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| UA78548C2 (en) * | 2002-03-29 | 2007-04-10 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and use thereof as metabotropic ligands of glutamate receptor |
| US7629362B2 (en) | 2003-02-13 | 2009-12-08 | Banyu Pharmaceutical Co., Ltd. | 2-pyridine carboxamide derivatives |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| US7507836B2 (en) * | 2003-03-26 | 2009-03-24 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
| JP2007524682A (ja) * | 2004-02-12 | 2007-08-30 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−5の調節物質としてのビピリジルアミド |
| US7414060B2 (en) * | 2005-03-04 | 2008-08-19 | Hoffmann-La Roche Inc. | Pyridine-2-carboxyamide derivatives |
-
2006
- 2006-02-23 US US11/360,085 patent/US7414060B2/en not_active Expired - Fee Related
- 2006-02-23 MX MX2007010414A patent/MX2007010414A/es active IP Right Grant
- 2006-02-23 CA CA2599974A patent/CA2599974C/en not_active Expired - Fee Related
- 2006-02-23 CN CN2006800070328A patent/CN101133027B/zh not_active Expired - Fee Related
- 2006-02-23 RU RU2007132655/04A patent/RU2411237C2/ru not_active IP Right Cessation
- 2006-02-23 ES ES06707197.7T patent/ES2476840T3/es not_active Expired - Lifetime
- 2006-02-23 BR BRPI0607583-5A patent/BRPI0607583A2/pt not_active IP Right Cessation
- 2006-02-23 JP JP2007557377A patent/JP4767975B2/ja not_active Expired - Fee Related
- 2006-02-23 EP EP06707197.7A patent/EP1858854B1/en not_active Expired - Lifetime
- 2006-02-23 KR KR1020077020093A patent/KR100929942B1/ko not_active Expired - Fee Related
- 2006-02-23 WO PCT/EP2006/001638 patent/WO2006094639A1/en not_active Ceased
- 2006-02-23 AU AU2006222289A patent/AU2006222289A1/en not_active Abandoned
- 2006-03-01 TW TW095106796A patent/TW200700391A/zh unknown
- 2006-03-02 AR AR20060100778A patent/AR054232A1/es not_active Application Discontinuation
-
2007
- 2007-08-16 IL IL185326A patent/IL185326A0/en unknown
- 2007-08-21 NO NO20074258A patent/NO20074258L/no not_active Application Discontinuation
- 2007-08-23 ZA ZA200707141A patent/ZA200707141B/xx unknown
-
2008
- 2008-07-01 US US12/165,758 patent/US20080269256A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1858854B1 (en) | 2014-05-07 |
| IL185326A0 (en) | 2008-02-09 |
| JP2008531618A (ja) | 2008-08-14 |
| CN101133027B (zh) | 2011-03-30 |
| AR054232A1 (es) | 2007-06-13 |
| BRPI0607583A2 (pt) | 2009-09-15 |
| WO2006094639A1 (en) | 2006-09-14 |
| EP1858854A1 (en) | 2007-11-28 |
| AU2006222289A1 (en) | 2006-09-14 |
| CA2599974A1 (en) | 2006-09-14 |
| ES2476840T3 (es) | 2014-07-15 |
| CN101133027A (zh) | 2008-02-27 |
| RU2007132655A (ru) | 2009-04-10 |
| US7414060B2 (en) | 2008-08-19 |
| KR100929942B1 (ko) | 2009-12-04 |
| MX2007010414A (es) | 2007-09-25 |
| JP4767975B2 (ja) | 2011-09-07 |
| KR20070107102A (ko) | 2007-11-06 |
| US20060199960A1 (en) | 2006-09-07 |
| ZA200707141B (en) | 2008-10-29 |
| TW200700391A (en) | 2007-01-01 |
| CA2599974C (en) | 2013-12-31 |
| US20080269256A1 (en) | 2008-10-30 |
| RU2411237C2 (ru) | 2011-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20083919L (no) | Pyridin- og pyrimidinderivater som mGluR2-antagonister | |
| TW200700391A (en) | Pyridine-2-carboxamide derivatives as mglur5 antagonists | |
| NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
| NO20073876L (no) | Pyrazolopyrimidinderivater som mGluR2-antagonister | |
| NO20092342L (no) | Azaspiroderivativater | |
| NO20091603L (no) | Kjemiske forbindelser | |
| NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
| NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20070339L (no) | 1-aza-bicyklo[3 3.1]nonaner | |
| NO20050828L (no) | lndol-3-svovelderivater | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| WO2008132139A3 (en) | New heterocyclic derivatives useful for the treatment of cns disorders | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| NO20091394L (no) | Pyridin-4-yl-derivater som immunmodulerende midler | |
| NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
| TW200801003A (en) | Novel compounds | |
| NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
| NO20081217L (no) | Nye benzotiazolonderivater | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| NO20082496L (no) | Pyrazinderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |